2 years ago

Mogrify Secures $10 Million in Additional Series A Funding for In Vivo Reprogramming Therapies

  • Mogrify, a UK-based biopharmaceutical company advancing in vivo reprogramming therapies, raised an additional $10 million in Series A funding, bringing the total raised in the round to $46 million

  • The round was led by Astellas Venture Management and Parkwalk Advisors, with participation from Ahren Innovation Capital, Trend Investment Group, and Dr

  • Jonathan Milner

  • The company intends to use the funds to advance its pipeline of in vivo reprogramming therapies through pre-clinical translation, platform optimization, and collaborations

  • Mogrify's pipeline aims to address degenerative diseases of the eye, ear, and pancreas by restoring clinically valuable cell types

  • The proceeds will be used to advance its pipeline, aiming for a Series B fundraise in 2024/25 and progression of a lead program into first-in-human studies.

      • ProblemHealthcare

      "Millions of people suffer from degenerative diseases like vision loss, hearing loss, and diabetes, which currently have limited treatment options."

      Solution

      "Mogrify has developed a platform that can identify the key genetic and epigenetic switches that control cell fate. This technology is used to develop therapies that reprogram cells in the body to restore their function, potentially providing a cure for these diseases."

      Covered on